Effect of prenatal zidovudine on disease progression in perinatally HIV-1 - Infected infants

Journal of Acquired Immune Deficiency Syndromes

Volumn 24, Issue 2, 2000, Pages 154-161

  De Souza, Ricardo S ^a   Gómez Marín, Orlando ^b   Scott, Gwendolyn B ^b   Guasti, Silvia ^c   O'Sullivan, Mary Jo ^c   Oliveira, Ricardo Hugo ^d   Mitchell, Charles D ^b  

^a UNIVERSITY OF CAXIAS DO SUL   (Brazil)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c Fundacao Municipal de Saude de Niteroi   (Brazil)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Perinatal HIV 1 infection; Prematurity; Rapid disease progression; Timing of transmission; Zidovudine

Indexed keywords

ZIDOVUDINE;

ADULT; ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PERINATAL INFECTION; PREGNANCY COMPLICATION; PREMATURITY; PRENATAL CARE; PRIORITY JOURNAL; VERTICAL TRANSMISSION;

EID: 0034209891     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200006010-00010     Document Type: Article

References (38)

1. Blanche S, Tardieu M, Duliege A-M, et al. Longitudinal study of 94 symptomatic infants with perinatally-acquired human immunodeficiency virus infection: evidence for a bimodal expression of clinical and biological symptoms. Am J Dis Child 1990;144: 1210-5.
2. Mayaux MJ, Burgard M, Tegals JP, et al. Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease. JAMA 1996;275:606-10.
3. Scott GB, Hutto C, Makuch RW, et al. Survival in children with perinatally acquired human immunodeficiency virus type 1 infection. N Engl J Med 1989;321:1791-6.
4. Auger I, Thomas P, De Grutolla V, et al. Incubation periods for paediatric AIDS patients. Nature 1988;336:575-7.
5. Commenges D, Alioum A, Lepage P, Van de Perre P, Msellati P, Dabis F. Estimating the incubation period of pediatric AIDS in Rwanda. AIDS 1992;6:1515-20.
6. Dickover RE, Dillon M, Gillete SG, et al. Rapid increases in load of human immunodeficiency virus correlate with early disease progression and loss of CD4 cells in vertically infected infants. J Infect Dis 1994;170:1279-84.
7. Stiehm ER. Newborn factors in maternal-infant transmission of pediatric HIV infection. J Nutr 1996;2632S-6S.
8. Blanche S, Mayaux MJ, Rouzioux C, et al. Relation of the course of HIV infection in children to the severity of the disease in their mothers at delivery. N Engl J Med 1994;330:308-12.
9. Tovo PA, de Martino M, Gabiano C, et al. AIDS appearance in children is associated with the velocity of disease progression in their mothers. J Infect Dis 1994;170:1000-2.
10. + cell count, acquired immunodeficiency syndrome, and viral load on disease progression in infants with perinatally acquired human immunodeficiency virus type 1 infection. J Pediatr 1997;130: 890-7.
11. Abrams EJ, Matheson PB, Thomas PA, et al. Neonatal predictors of infection status and early death among 332 infants at risk of HIV-1 infection monitored prospectively from birth. Pediatrics 1995;96:451-8.
12. Just JJ, Abrams EJ, Louie LG, et al. Influence of host genotype on progression to acquired immunodeficiency syndrome among children infected with human immunodeficiency virus type 1. J Pediatr 1995;127:544-9.
13. Spencer LT, Ogino MT, Danker WM, Spector SA. Clinical significance of human immunodeficiency virus type 1 phenotypes in infected children. J Infect Dis 1994;169:491-5.
14. Phyllis JK, Donald JH, Jean-Louis Sankalé, et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 1999;179:68-73.
15. + lymphocyte count in HIV-infected infants and children. JAMA 1998;279:765-61.
16. De Rossi A, Masiero S, Giaquinto C, et al. Dynamics of viral replication in infants with vertically acquired human immunodeficiency virus type 1 infection. J Clin Invest 1996;97:323-30.
17. Shearer WT, Quinn TC, LaRussa P, Lew JF, Mofenson L, Almy S. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med 1997;336:1337-42.
18. Mofenson LM, Korelitz J, Meyer WA, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1 infected children. J Infect Dis 1997;175:1029-38.
19. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with Zidovudine treatment. N Engl J Med 1994;331:1173-80.
20. Dickover RE, Garratty EM, Herman SA, et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission - effect of maternal zidovudine treatment on viral load. JAMA 1996;275:599-605.
21. Kuhn L, Steketee W, Weedon W, et al. Distinct risk factors for intrauterine and intrapartum human immunodeficiency virus transmission and consequences for disease progression in infected children. J Infect Dis 1999;179:52-8.
22. Shaffer N, Chuachoowong R, Mock PA, et al. Short course zidovudine for perinatal HIV-1 transmission in Bankok, Thailand: a randomized controlled trial. Lancet 1999;353:773-80.
23. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998;339:1409-14.
24. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41(RR-17):1-19.
25. Centers for Disease Control and Prevention. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep 1994;43:1-7.
26. Cary, NC: SAS Institute Inc.
27. Kaplan EL, Meier P. Nonparametric estimates from incomplete observations. J Am Stat Assoc 1958;53:457-81.
28. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc 1972;135:185-207.
29. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39.
30. Bryson Y, Luzuriaga K, Sullivan L. Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med 1992;327:1246-7.
31. Kuhn L, Abrams EJ, Matheson PB, Thomas PA, Lambert G, Bamji M. Timing of maternal-infant HIV transmission: associations between intrapartum factors and early polymerase chain reaction results. New York City Perinatal HIV. AIDS 1997;11:429-35.
32. Martino M. Rapid disease progression in HIV-1 perinatally infected children born to mothers receiving zidovudine monotherapy during pregnancy. The Italian Register for HIV Infection in Children. AIDS 1999;13:927-33.
33. Blanche S, Newell ML, Mayaux MJ, et al. Morbidity and mortality in European children vertically infected by HIV-1. The French Pediatric HIV Infection Study Group and European Collaborative Study. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14: 442-50.
34. Fiscus SA, Adimora AA, Schoenbach VJ, at al. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban countries. JAMA 1996;275:1483-8.
35. Cooper ER, Nugent RP, Diaz C, et al. After AIDS Clinical Trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. J Infect Dis 1996;174:1207-11.
36. Matheson PB, Abrams EJ, Thomas PA, Hernan MA, Thea DM, Lambert G. Efficacy of antenatal zidovudine in reducing perinatal transmission of human immunodeficiency virus type 1. The New York City Perinatal HIV Transmission Collaborative Study Group. J Infect Dis 1995;172:353-8.
37. Frenkel LM, Cowles MK, Shapiro DE, et al. Analysis of maternal components of the AIDS clinical trial group zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1. J Infect Dis 1997; 175:971-4.
38. Sperling RS, Shapiro DE, Coombs RW, Todd JA, Herman SA, McSherry GD. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1996;335:1621-9.